Premium
The safe use of cisplatin in hyperthermic isolated limb perfusion systems
Author(s) -
Roseman James M.,
Tench Daniel,
Bryant Lester R.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850815)56:4<742::aid-cncr2820560407>3.0.co;2-1
Subject(s) - cisplatin , medicine , nephrotoxicity , perfusion , drug , hyperthermia , chemotherapy , systemic administration , renal function , systemic therapy , oncology , pharmacology , basal cell , kidney , urology , surgery , cancer , in vivo , microbiology and biotechnology , biology , breast cancer
A patient presenting with aggressive squamous cell carcinoma successfully received cisplatin chemotherapy via hyperthermic, isolated limb perfusion (renal impairment ruled out systemic use). Human tumor stem cell assay identified cisplatin as the drug of choice and supports the potential benefit of this procedure in single therapeutic situations. The case illustrates the safety of cisplatin and the ability to give large doses of the nephrotoxic drug with no damage to renal function. The potential efficacy over systemic cisplatin has yet to be established except when systemic use is limited from renal dysfunction.